Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5918893 | 0.82 | PPARD (0.50) | TSHRPPARDTP53TDP1THRB | |
| SCHEMBL11217298 | 0.81 | TSHR (0.33) | TSHRTHRBLMNAMEN1KMT2A | |
| SCHEMBL8157090 | 0.81 | TSHR (0.50) | TSHRPPARDTP53TDP1MAPT | |
| SCHEMBL16975426 | 0.79 | TSHR (0.40) | TSHRPPARDTP53TDP1THRB | |
| SCHEMBL24384243 | 0.79 | TSHR (0.43) | TSHRPPARDTP53TDP1MAPT | |
| SCHEMBL28029802 | 0.77 | TSHR (0.41) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL9179421 | 0.76 | TSHR (0.62) | TSHRPPARDTP53TDP1 | |
| SCHEMBL9633264 | 0.75 | TSHR (0.55) | TSHRPPARDTP53TDP1MAPT | |
| SCHEMBL8970570 | 0.74 | TSHR (0.36) | TSHRTP53TDP1 | |
| SCHEMBL29249469 | 0.73 | THRB (0.35) | TSHRTHRBLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640688-A1 | AVERMECTIN DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2025-10-29 | — | — | EP | disclosed |
| CN-119119704-A | Polycarbonate resin film | 三菱化学株式会社 | 2024-12-13 | — | — | CN | disclosed |
| CN-119119705-A | Polycarbonate resin film | 三菱化学株式会社 | 2024-12-13 | — | — | CN | disclosed |
| EP-3214109-B1 | POLYCARBONATE RESIN, MOLDED ARTICLE AND OPTICAL FILM | MITSUBISHI CHEM CORP (JP) | 2024-08-21 | — | — | EP | disclosed |
| WO-2024135828-A1 | AVERMECTIN DERIVATIVE | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 2024-06-27 | — | — | WO | disclosed |
| US-20230340259-A1 | RESIN COMPOSITION, MOLDED ARTICLE, AND MACROMONOMER COPOLYMER | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-10-26 | — | — | US | disclosed |
| EP-4253438-A1 | RESIN COMPOSITION, MOLDED ARTICLE, AND MACROMONOMER COPOLYMER | Mitsubishi Chemical Corporation (JP) | 2023-10-04 | — | — | EP | disclosed |
| US-11730746-B2 | 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure | CVIE THERAPEUTICS LIMITED (TW) | 2023-08-22 | — | — | US | disclosed |
| US-11730746-B2 | 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure | CVIE THERAPEUTICS LIMITED (TW) | 2023-08-22 | — | — | US | disclosed |
| WO-2023074576-A1 | POLYCARBONATE RESIN | 三菱ケミカル株式会社 | 2023-05-04 | — | — | WO | disclosed |
| EP-0378991-A1 | Certain pyrrolylphenyl-substituted hydroxamic acid derivatives | CIBA-GEIGY AG (CH) | 1990-07-25 | — | — | EP | disclosed |
| WO-1989012051-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | disclosed |
| WO-1989012054-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | disclosed |
| WO-1989012053-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | disclosed |
| WO-1989012050-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | disclosed |
| EP-0344982-A2 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
| EP-0344979-A2 | Alfa-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
| EP-0344981-A2 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
| EP-0344980-A2 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
| US-4879069-A | DIAGNOSIS OF CHOLESTEROL LEVEL | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1989-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730746-B2 | 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure | CYP8B1, CYP24A1, NPPA | TSHR 3873/4885PPARD 955/4885TP53 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.